Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activity
Ryan A. Lafferty, Neil Tanday, Peter R. Flatt, et al.
Metabolism (2020) Vol. 111, pp. 154339-154339
Open Access | Times Cited: 9

Showing 9 citing articles:

Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies
Manuel Lisardo Sánchez, Francisco D. Rodríguez, Rafael Coveñas
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 9962-9962
Open Access | Times Cited: 23
Neuropeptide Y and Metabolism Syndrome: An Update on Perspectives of Clinical Therapeutic Intervention Strategies
Yinqiong Huang, Xiahong Lin, Shu Lin
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 43
Evolution of peptide YY analogs for the management of type 2 diabetes and obesity
Wang Chen, Gong Binbin, Lidan Sun, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106808-106808
Closed Access | Times Cited: 14
Established and emerging roles peptide YY (PYY) and exploitation in obesity–diabetes
Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
Current Opinion in Endocrinology Diabetes and Obesity (2020) Vol. 28, Iss. 2, pp. 253-261
Open Access | Times Cited: 39
NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?
Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
Peptides (2024) Vol. 179, pp. 171256-171256
Open Access | Times Cited: 1
Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity
Jing Xu, Shuang Wang, Han Wu, et al.
Peptides (2023) Vol. 169, pp. 171073-171073
Closed Access | Times Cited: 3
Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed mice
Ryan A. Lafferty, Laura M. McShane, Zara J. Franklin, et al.
Journal of Endocrinology (2022) Vol. 255, Iss. 2, pp. 91-101
Open Access | Times Cited: 5
The glucagon receptor antagonist desHis1Pro4Glu9-glucagon(Lys12PAL) alters alpha-cell turnover and lineage in mice, but does not cause alpha-cell hyperplasia
Ryan A. Lafferty, Neil Tanday, Vaibhav Dubey, et al.
Molecular and Cellular Endocrinology (2023) Vol. 570, pp. 111932-111932
Open Access | Times Cited: 2
Pharmacology of Gut Hormone Mimetics for Obesity and Diabetes
Ryan A. Lafferty, Finbarr O’Harte, Nigel Irwin, et al.
Elsevier eBooks (2021), pp. 301-343
Closed Access | Times Cited: 1
Page 1

Scroll to top